eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


2/2011
vol. 10
 
Share:
Share:
abstract:
Original paper

Podoplanin expression in malignant ovarian cancer

Barbara Marzec-Kotarska
,
Józef Kotarski
,
Marek Cybulski
,
Halina Antosz
,
Janusz Kocki
,
Wiesława Bednarek

Przegląd Menopauzalny 2011; 2: 102–105
Online publish date: 2011/04/28
View full text Get citation
 
Introduction: Ovarian cancer is mostly diagnosed in postmenopausal women. The hormonal microenviron-

ment of ovarian tumour development in pre- and postmenopausal women is different. The environment may influence the molecular basis of ovarian cancer. Podoplanin is a proven marker of lymphangiogenesis and is engaged in tumour progression and metastasis.

Objectives: The aim of our study was to assess podoplanin expression at the mRNA level in ovarian serous and mucinous adenocarcinoma.

Material and methods : mRNA expression of podoplanin was assessed in 42 ovarian cancer patients by means of real-time PCR.

Results : Podoplanin was expressed at the mRNA level in all ovarian cancer patients. It was significantly lower (p < 0.001) in cancer tissues (RQ = 4.46) than in healthy control (RQ = 13.03). No significant differences were found in podoplanin expression either between pre- and postmenopausal women or in relation to FIGO and grading

Conclusion : Decreased podoplanin expression is characteristic for serous and mucinous ovarian adenocarcinoma.
keywords:

podoplanin, ovarian cancer

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.